DEVELOPMENT OF NOVEL TETRACYCLINE COUNTERMEASURES FOR RESPIRATORY DISEASES
$2,901,309N01FY2014AINIH
Cubrc, Inc., Buffalo NY
Investigators
Abstract
This contract supports the advanced development of promising biodefense therapeutic candidates/products with broad spectrum activity. The research and development activities supported will allow candidate therapeutic countermeasures to progress through the product development pipeline, and includes preclinical/non-clinical and clinical IND translational development activities.
View original record on NIH RePORTER →